JP2021502977A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502977A5 JP2021502977A5 JP2020526445A JP2020526445A JP2021502977A5 JP 2021502977 A5 JP2021502977 A5 JP 2021502977A5 JP 2020526445 A JP2020526445 A JP 2020526445A JP 2020526445 A JP2020526445 A JP 2020526445A JP 2021502977 A5 JP2021502977 A5 JP 2021502977A5
- Authority
- JP
- Japan
- Prior art keywords
- srsf3
- fragment
- agonist
- nervous system
- central nervous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762586567P | 2017-11-15 | 2017-11-15 | |
| US62/586,567 | 2017-11-15 | ||
| PCT/CA2018/051452 WO2019095064A1 (en) | 2017-11-15 | 2018-11-15 | Use of srsf3 agents for the treatment and/or prevention of neurological conditions, cancer, bacterial infections or viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021502977A JP2021502977A (ja) | 2021-02-04 |
| JP2021502977A5 true JP2021502977A5 (https=) | 2021-12-23 |
Family
ID=66539186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526445A Pending JP2021502977A (ja) | 2017-11-15 | 2018-11-15 | 神経学的状態、がん、細菌性感染症又はウイルス性感染症の治療及び／又は予防のためのｓｒｓｆ３作用剤の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11530258B2 (https=) |
| EP (1) | EP3710015B1 (https=) |
| JP (1) | JP2021502977A (https=) |
| CN (1) | CN111556761A (https=) |
| CA (1) | CA3095354A1 (https=) |
| WO (1) | WO2019095064A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CN115927190B (zh) * | 2022-05-10 | 2025-06-27 | 山东第一医科大学(山东省医学科学院) | 一种稳定过表达srsf3的raw 264.7细胞系、其制备方法及应用 |
| CN116376910B (zh) * | 2022-12-30 | 2023-09-29 | 郑州大学第二附属医院 | 一种三叉神经痛的标志物及治疗三叉神经的药物 |
| CN120464626A (zh) * | 2025-07-15 | 2025-08-12 | 赤峰市医院 | 敲低BST2基因表达的shRNA、重组载体及应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040156826A1 (en) * | 2002-09-27 | 2004-08-12 | Fernando Dangond | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
| US20070015172A1 (en) * | 2005-06-01 | 2007-01-18 | Z-Biomed, Inc. | Expression profiles for microbial infection |
| TW201122480A (en) * | 2009-10-26 | 2011-07-01 | Abbott Lab | Diagnostic methods for determining prognosis of non-small cell lung cancer |
| US20140220690A1 (en) * | 2009-11-11 | 2014-08-07 | Vanderbilt University | Mammalian genes involved in infection |
| KR101811462B1 (ko) * | 2010-01-11 | 2018-01-25 | 피닉스 바이오테크놀러지 인코포레이티드. | 협죽도 추출물을 포함하는 신경질환 치료용 조성물 |
| WO2012045067A2 (en) | 2010-10-01 | 2012-04-05 | Zirus, Inc. | Mammalian genes involved in infection |
| US10078086B2 (en) | 2012-08-31 | 2018-09-18 | Childrens Hospital Medical Center | Use of interleukin-27 as a diagnostic biomarker for bacterial infection in critically ill patients |
| US11047010B2 (en) * | 2014-02-06 | 2021-06-29 | Immunexpress Pty Ltd | Biomarker signature method, and apparatus and kits thereof |
| WO2015143343A2 (en) | 2014-03-21 | 2015-09-24 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
| US12241053B2 (en) * | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
-
2018
- 2018-11-15 WO PCT/CA2018/051452 patent/WO2019095064A1/en not_active Ceased
- 2018-11-15 EP EP18879970.4A patent/EP3710015B1/en active Active
- 2018-11-15 CN CN201880085580.5A patent/CN111556761A/zh active Pending
- 2018-11-15 CA CA3095354A patent/CA3095354A1/en active Pending
- 2018-11-15 US US16/763,906 patent/US11530258B2/en active Active
- 2018-11-15 JP JP2020526445A patent/JP2021502977A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102197524B1 (ko) | 특발성 폐 섬유증의 예후, 진단 및 치료 방법 | |
| JP2021502977A5 (https=) | ||
| EP2473636B1 (en) | Type 1 interferon diagnostic | |
| CN107109494B (zh) | Il-33介导型疾病的治疗方法和诊断方法 | |
| JP2021535489A5 (https=) | ||
| AU2016213773B2 (en) | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-MAF | |
| JP2015504430A (ja) | Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法 | |
| US20150086570A1 (en) | Biomarkers for use in integrin therapy applications | |
| FI3774897T3 (fi) | Menetelmiä ja järjestelmiä tulehdustautisten potilaiden valintaan ja hoitoon | |
| KR20110081758A (ko) | 강직성척추염 진단용 프라이머 및 이를 이용한 강직성 척추염 진단 방법 | |
| RU2016132162A (ru) | Способы лечения болезни альцгеймера | |
| JP2022046486A (ja) | 眼障害を治療する方法 | |
| JP2017513937A (ja) | Ｉｌ−１３アンアゴニストを用いて喘息を選択的に治療する方法 | |
| KR20150010709A (ko) | Il-17 길항제를 사용하는 강직성 척추염의 치료 방법 | |
| JP2025169256A (ja) | α４β７阻害薬及びＩＬ－２３阻害薬の併用療法 | |
| WO2014155278A2 (en) | Methods of treating autoimmune diseases using il-17 antagonists | |
| CN105296659B (zh) | 一种与缺血性脑卒中相关的基因标记物 | |
| WO2011045349A2 (en) | Methods for diagnosing and treating a pathology associated with a synonymous mutation occuring within a gene of interest | |
| JP2022521973A (ja) | 抗ｃｄ６抗体組成物およびループスを処置するための方法 | |
| JPWO2019212899A5 (https=) | ||
| WO2003026488A3 (en) | Diagnosis and treatment of vascular disease | |
| JP5399219B2 (ja) | 関節リウマチに対するヒト型抗ＴＮＦα抗体薬の薬効予測方法、及び薬効予測装置 | |
| Gillett et al. | Interleukin 18 receptor 1 expression distinguishes patients with multiple sclerosis | |
| JP2013021932A (ja) | 関節リウマチに対する抗ｉｌ−６受容体抗体療法の有効性の予測方法 | |
| JP5879665B2 (ja) | ＰＤＥ８Ａ ｍＲＮＡ前駆体の編集プロファイリング：治療効力および／もしくは有効性または潜在的薬物副作用を診断するため、ならびに予測および評価するための、ヒト組織における特異的バイオマーカーとしてのＡＤＡＲｓ活性の使用 |